Skip to main content

Publications

FOLLOWING ECIL 5

Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. C Cordonnier, S Cesaro, G Maschmeyer, H Einsele, J P Donnelly, A Alanio, P M. Hauser, K Lagrou, W J G Melchers, J Helweg-Larsen, O Matos, S Bretagne and J Maertens. Journal of Antimicrobial Chemotherapy 2016, doi:10.1093/jac/dkw155. 

download

ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with hematological malignancies and stem cell transplant recipients J Maertens, S Cesaro, G Maschmeyer, H Einsele, J P Donnelly, A Alanio, P M. Hauser, K Lagrou, W J G Melchers, J Helweg-Larsen, O Matos, S Bretagne and C Cordonnier Journal of Antimicrobial Chemotherapy 2016, doi:10.1093/jac/dkw157

ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with hematological malignancies and stem cell transplant recipients A Alanio, P M. Hauser, K Lagrou, W J G Melchers, J Helweg-Larsen, O Matos, S Cesaro, G Maschmeyer, H Einsele, J P Donnelly, C Cordonnier, J Maertens, S Bretagne Journal of Antimicrobial Chemotherapy 2016, doi:10.1093/jac/dkw156 Download

Response to “Comment on Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients ”by S. Antinori and colleagues.
C CORDONNIER, A ALANIO, S CESARO, G MASCHMEYER, H EINSELE, J. P DONNELLY, P M. HAUSER, K LAGROU, W J. G. MELCHERS, J HELWEG-LARSEN, O MATOS, S BRETAGNE, J MAERTENS on behalf of the 5th European Conference on Infections in Leukemia.
J. Antimicrob. Chemother. 2017 Jan 25. pii: dkw580. doi: 10.1093/jac/dkw580. [Epub ahead of print]

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haematopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukemia.
V MALLET, F VAN BÖMMEL, C DOERIG, S PISCHKE, O HERMINE, A LOCASCIULLI, C CORDONNIER, T BERG, D MORADPOUR, H WEDEMEYER, P LJUNGMAN, on behalf of ECIL 5, a joint venture of EBMT, EORTC, ICHS and ELN.
Lancet Infectious Diseases 2016, 16 : 606-17